Tigecycline in Bloodstream Infections

Critical Limitations of Tigecycline in Bloodstream Infections

• Tigecycline achieves a maximum serum concentration (Cmax) of only 0.87 mg/L with standard dosing, which is inadequate for treating intravascular infections 4
• The large volume of distribution results in low serum levels despite tissue penetration 4
• Tigecycline monotherapy is associated with a 2.73-fold increased odds of mortality (OR 2.73, 95% CI 1.53-4.87) compared to tigecycline-based combination therapy in bloodstream infections 1, 2, 3

When Tigecycline May Have a Role

• High-dose tigecycline (200 mg loading dose, then 100 mg q12h) combined with other active agents showed significantly lower mortality (OR 0.44, 95% CI 0.30-0.66) compared to standard-dose regimens 1, 2, 3
• Tigecycline should only be used when the isolate MIC is ≤0.5 mg/L 1, 2, 3
• For KPC-producing carbapenem-resistant Klebsiella pneumoniae bloodstream infections, tigecycline significantly reduced mortality (OR 0.64, 95% CI 0.42-0.97) 1, 2, 3

Dosing Algorithm for Bloodstream Infections

• High-dose regimen required: 200 mg IV loading dose, followed by 100 mg IV q12h 1, 2, 3, 8
• Standard dosing (100 mg loading, 50 mg q12h) is inadequate for bloodstream infections and associated with higher mortality 1, 2, 3

Critical Caveats and Pitfalls

• Never use tigecycline as monotherapy for any bloodstream infection due to documented increased mortality 1, 2, 3
• Only use tigecycline when isolate MIC is ≤0.5 mg/L 1, 2, 3
• For CRE bloodstream infections, newer beta-lactam/beta-lactamase inhibitors (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) are preferred when active 3
• For Acinetobacter bloodstream infections, colistin-based combination therapy remains first-line 5